The prevalence of EGFR and HER2 co-amplification has been reported as low (<0.5 %) [15, 16], albeit studies analysing concurrent EGFR and HER2 GCN changes are few and none have been carried out after the novel molecular subtypes of gastric cancer were published [2]. The gene discussed is EGFR; the disease is gastric cancer.